Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 10, 2013

View Archived Issues

Small-molecule lipid II inhibitors identified as potential antibacterials

NDC-1308, a novel compound inducing remyelination and slowing clinical signs in EAE mice

S. pneumoniae whole-cell vaccine undergoes phase I study

Alkermes completes enrollment in pivotal study of aripiprazole lauroxil

Three clinical studies of Parkinson's disease candidate opicapone reported

WISP1 gene expression linked to adipose tissue differentiation and obesity

Gicare Pharma develops compounds for visceral pain

Novel PCSK9 expression inhibitors described in Kowa patent

U.S. researchers design prodrugs of riluzole

Mileutis divulges peptides for lactation disorders

Sysmex Inostics and Bayer HealthCare to develop blood-based companion diagnostic tests

Molecular Templates raises funds to advance MT-3724

The Medicines Company and Alnylam to advance ALN-PCSsc

Ariad Pharmaceuticals gives update on Iclusig development

Immunogenicity and efficacy of HIVAX vaccine: results of a first-in-human study

CGEN-15001 is effective in an animal model of type 1 diabetes

FDA accepts filing for Bunavail NDA

Promedior begins phase II study of PRM-151 in myelofibrosis

Phase I/II study of Portola Pharmaceuticals' dual SYK/JAK inhibitor commences

QRxPharma meets with the FDA regarding MoxDuo NDA

Novogen acquires new technology targeting the Tm5NM1 protein

Phase III bivalirudin trial enrolls first patient

Kowa seeks approval in Japan for K-115

Morphotek reports initiation of phase I study of MORAb-004 in pediatric patients

Positive risk-benefit leads Gilead to end phase III study of idelalisib early

Nycomed to return worldwide rights to veltuzumab

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...